Novavax, Inc. (NVAX) announced on Friday that its COVID-19 Vaccine, Adjuvanted (2024-2025 Formula), has been granted Emergency Use Authorization by the U.S. Food and Drug Administration. This authorization permits its use for active immunization in individuals aged 12 and older.The vaccine is part of the recommendations issued by the U.S. Centers for Disease Control and Prevention (CDC) on June 27, 2024.Post the release of vaccine batches from the Center for Biologics Evaluation and Research, pre-filled syringes of the vaccine will be available at numerous locations, including retail and independent pharmacies and regional grocery stores.”Today’s authorization paves the way for Novavax to introduce our updated COVID-19 vaccine across the U.S. in pre-filled syringes. We have made significant efforts to ensure that consumers can access the vaccine at thousands of locations nationwide,” stated John C. Jacobs, President and Chief Executive Officer of Novavax. “Our updated vaccine targets the JN.1 ‘parent strain’ of the currently circulating variants and has demonstrated strong cross-reactivity against JN.1 lineage viruses, including KP.2.3, KP.3, KP.3.1.1, and LB.1.”In June, the CDC’s Advisory Committee on Immunization Practices unanimously recommended the universal usage of the 2024-2025 COVID-19 vaccines for all individuals aged six months and older, regardless of specific viral strains, under Emergency Use Authorization or Biologics License Application approval.The material has been provided by InstaForex Company – www.instaforex.com
- Latvia Trade Deficit Widens In July - September 10, 2024
- Helmerich & Payne To Issue Private Offering Of Senior Notes - September 10, 2024
- Fluent Confirms Ryan Perfit As CFO - September 10, 2024
